Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Unknown 1 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 488 Lymphoma, T-Cell, Cutaneous 92 Carcinoma, Non-Small-Cell Lung 89 Mycosis Fungoides 72 Neoplasm Metastasis 71 Skin Neoplasms 62 Neoplasms 61 Sezary Syndrome 60 Carcinoma, Renal Cell 60 Lymphoma, Non-Hodgkin 53 Lymphoma, Large B-Cell, Diffuse 53 Lymphoma 53 Breast Neoplasms 52 Leukemia, Lymphocytic, Chronic, B-Cell 50 Lymphoma, Follicular 47 Lymphoma, Mantle-Cell 46 Lymphoma, B-Cell, Marginal Zone 46 Squamous Cell Carcinoma of Head and Neck 45 Precursor Cell Lymphoblastic Leukemia-Lymphoma 44 Hodgkin Disease 44 Colorectal Neoplasms 43 Burkitt Lymphoma 43 Lymphoma, Large-Cell, Immunoblastic 41 Ovarian Neoplasms 38 Multiple Myeloma 35 Uveal Melanoma 34 Leukemia, Hairy Cell 33 Lymphoma, Large-Cell, Anaplastic 32 Sarcoma 31 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 31

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Melanoma × Dermatologic × Clear all

NCT03407170 2020-07-15

KEYNOTE-161

Merck Sharp & Dohme LLC

Phase 2 Terminated

1 enrolled 3 charts

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡